Usted buscó: mrsa (Inglés - Croata)

more than 80% of mrsa express cmlsb.
više od 80% mrsa izražavaju cmlsb.

staphylococcus aureus methicillin resistant (mrsa)+
staphylococcus aureus rezistentan na meticilin (mrsa)+

methicillin-resistant staphylococcus aureus (mrsa)
meticilin-rezistentan staphylococcus aureus (mrsa)

no cases of cap due to mrsa were enrolled into the studies.
u ispitivanja nije bio uključen niti jedan slučaj izvanbolnički stečene pneumonije čiji je uzročnik bila mrsa.

an association between persistent isolation of mrsa and worse clinical outcome has been reported in the literature.
povezanost između ustrajne izolacije mrsa-e i lošijeg kliničkog ishoda zabilježena je u literaturi.

an association between persistent isolation of mrsa and more severe disease and increased mortality has been reported in the literature.
povezanost između trajne izolacije mrsa i ozbiljnijih bolesti te povećane smrtnosti zabilježena je u literaturi.

in clinical studies of secondarily infected open wounds, the efficacy of retapamulin was inadequate in patients with infections caused by mrsa.
u kliničkim ispitivanjima sekundarno inficiranih otvorenih rana, djelotvornost retapamulina nije bila primjerena u bolesnika s infekcijama uzrokovanima mrsa-om.

$: the response rate for mrsa due to pvl+ mrsa was 8/13 (62%)
$: stopa odgovora za mrsa uslijed pvl+ mrsa bila je 8/13 (62%)

# methicillin-resistant staphylococci (including mrsa) are always resistant to betalactams.
# stafilokoki rezistentni na meticilin (uključujući mrsa) uvijek su rezistentni na beta-laktame.

retapamulin should not be used to treat infections known or thought likely to be due to mrsa (see section 5.1).
retapamulin se ne smije koristiti za liječenje infekcija za koje se zna ili se pretpostavlja da su uzrokovane mrsa-om (vidjeti dio 5.1).

during the 6-month randomised phase of study gs-us-205-0110, treatment-emergent isolation of mssa and mrsa was observed more commonly among aztreonam-treated patients than tobramycin nebuliser solution (tns)-treated patients.
tijekom 6-mjesečne randomizirane faze ispitivanja gs-us-205-0110, izolacija mssa-e i mrsa-e prouzročenih liječenjem, primijećena je više kod bolesnika liječenih aztreonamom nego s otopinom tobramicina za atomizator (tns-om, tobramycin nebuliser solution).